​

Aclaris Therapeutics (ACRS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ACRS Stock Forecast

Aclaris Therapeutics (ACRS) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $8.00 and a low of $3.00. This represents a 351.13% increase from the last price of $1.33.

$1 $2 $3 $4 $5 $6 $7 $8 High: $8 Avg: $6 Low: $3 Last Closed Price: $1.33

ACRS Stock Rating

Aclaris Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (78.57%), 3 Hold (21.43%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 3 11 Strong Sell Sell Hold Buy Strong Buy

ACRS Price Target Upside V Benchmarks

TypeNameUpside
StockAclaris Therapeutics351.13%
SectorHealthcare Stocks 30.37%
IndustryDiagnostics & Research Stocks33.90%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$6.00
Last Closing Price$1.33$1.33$1.33
Upside/Downside--351.13%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25241--7
Mar, 25231--6
Feb, 25231--6
Jan, 25232--7
Dec, 24233--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 19, 2024Julian HarrisonBTIG$8.00$3.14154.78%501.50%
Nov 19, 2024Roger SongJefferies$7.00$3.14122.93%426.32%
Nov 06, 2024Alex ThompsonStifel Nicolaus$3.00$2.2831.58%125.56%
Dec 01, 2022Goldman Sachs$25.00$15.2264.26%1779.70%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 07, 2025ScotiabankOutperforminitialise
Nov 20, 2024Cantor FitzgeraldOverweightupgrade
Nov 19, 2024Leerink PartnersOutperformupgrade
Sep 18, 2024H.C. WainwrightNeutralNeutralhold
Sep 18, 2024BTIGNeutralNeutralhold
Jan 11, 2024Stifel NicolausBuyBuyhold
Dec 18, 2023H.C. WainwrightUnderperformUnderperformhold
Dec 18, 2023Stifel NicolausBuyBuyhold
Mar 07, 2023BTIGBuyBuyhold
Dec 01, 2022Goldman SachsBuyinitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.20$-2.01$-1.36$-1.27$-1.71----
Avg Forecast$-1.84$-1.61$-1.44$-1.61$-0.82$-0.59$-0.65$-0.71$-0.59
High Forecast$-0.37$-0.33$-0.31$-1.52$-0.57$-0.45$-0.49$-0.60$0.02
Low Forecast$-4.46$-3.90$-3.76$-1.66$-1.12$-0.99$-0.94$-0.86$-1.28
Surprise %-34.78%24.84%-5.56%-21.12%108.54%----

Revenue Forecast

$0 $17M $34M $51M $68M $85M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.48M$6.76M$29.75M$31.25M$18.72M----
Avg Forecast$6.29M$7.05M$23.99M$18.34M$11.62M$11.97M$8.29M$6.96M$42.43M
High Forecast$13.19M$14.78M$53.87M$24.25M$13.77M$21.72M$15.66M$13.14M$80.13M
Low Forecast$2.44M$2.73M$9.48M$14.96M$10.06M$2.80M$1.74M$1.46M$8.90M
Surprise %2.97%-4.13%24.00%70.40%61.15%----

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-51.15M$-114.28M$-88.66M$-88.48M$-132.06M----
Avg Forecast$-51.47M$-77.55M$-87.16M$-88.48M$-58.98M$-61.52M$-49.98M$-50.91M$-41.42M
High Forecast$-41.18M$-62.04M$-69.73M$-70.78M$-39.55M$-31.59M$-34.03M$-42.02M$1.13M
Low Forecast$-61.76M$-93.06M$-104.59M$-106.18M$-78.40M$-68.80M$-65.94M$-59.80M$-89.27M
Surprise %-0.61%47.36%1.73%-123.93%----

ACRS Forecast FAQ

Is Aclaris Therapeutics stock a buy?

Aclaris Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aclaris Therapeutics is a favorable investment for most analysts.

What is Aclaris Therapeutics's price target?

Aclaris Therapeutics's price target, set by 14 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $3 at the low end to $8 at the high end, suggesting a potential 351.13% change from the previous closing price of $1.33.

How does Aclaris Therapeutics stock forecast compare to its benchmarks?

Aclaris Therapeutics's stock forecast shows a 351.13% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and outperforming the diagnostics & research stocks industry (33.90%).

What is the breakdown of analyst ratings for Aclaris Therapeutics over the past three months?

  • April 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Aclaris Therapeutics’s EPS forecast?

Aclaris Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.59, marking a -65.50% decrease from the reported $-1.71 in 2024. Estimates for the following years are $-0.65 in 2026, $-0.71 in 2027, and $-0.59 in 2028.

What is Aclaris Therapeutics’s revenue forecast?

Aclaris Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $11.97M, reflecting a -36.05% decrease from the reported $18.72M in 2024. The forecast for 2026 is $8.29M, followed by $6.96M for 2027, and $42.43M for 2028.

What is Aclaris Therapeutics’s net income forecast?

Aclaris Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-61.516M, representing a -53.42% decrease from the reported $-132M in 2024. Projections indicate $-49.984M in 2026, $-50.912M in 2027, and $-41.42M in 2028.